AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03704532 — intervention group
Intervention type: PROCEDURE
Intervention: Operative treatment
Description: Open surgical repair of tendon rupture
Study NCT03704532 — intervention group
Intervention type: PROCEDURE
Intervention: Nonoperative treatment
Description: Nonoperative treatment with lower leg orthosis and functional rehabilitation
Study NCT03193671 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: Improving diagnosis
Study NCT00345384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine titrated over 24 hours
Study NCT00345384 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal Saline)
Study NCT05016414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure
Description: lower body negative pressure at -20mmHg delivered via a custom designed sleeping sack
Study NCT00885352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg tablet orally once daily for 26 weeks.
Study NCT00885352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo to sitagliptin 100 mg tablet orally once daily for 26 weeks.
Study NCT00885352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: Participants taking 30 mg or more pioglitazone oral tablet(s) daily at screening in combination with metformin will enter a 4-week dose-stable period followed by a 2-week single-blind run-in and a 26-week treatment period. Participants taking 4 mg or more rosiglitazone oral tablet(s) daily at screening in combination with metformin were to be switched to a corresponding dose of pioglitazone prior to starting a 4-week dose-stable period. Participants who are taking less than 30 mg/day or no pioglitazone at screening will be titrated to a stable dose of at least 30 mg pioglitazone once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with pioglitazone will be up to 42 weeks.
Study NCT00885352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Participants taking 30 mg or more pioglitazone oral tablet(s) daily at screening in combination with metformin will enter a 4-week dose-stable period followed by a 2-week single-blind run-in and a 26-week treatment period. Participants taking 4 mg or more rosiglitazone oral tablet(s) daily at screening in combination with metformin were to be switched to a corresponding dose of pioglitazone prior to starting a 4-week dose-stable period. Participants who are taking less than 30 mg/day or no pioglitazone at screening will be titrated to a stable dose of at least 30 mg pioglitazone once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with pioglitazone will be up to 42 weeks.
Study NCT00885352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Participants taking 1500 mg or more metformin oral tablet(s) and at least 30 mg pioglitazone or 4 mg rosiglitazone daily at screening will enter a 4-week dose-stable period followed by a 2-week single-blind placebo run-in, and a 26-week treatment period. Participants who are taking less than 1500 mg/day metformin at screening will be titrated to a stable dose of at least 1500 mg metformin once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with metformin will be up to 42 weeks.
Study NCT00885352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants taking 1500 mg or more metformin oral tablet(s) and at least 30 mg pioglitazone or 4 mg rosiglitazone daily at screening will enter a 4-week dose-stable period followed by a 2-week single-blind placebo run-in, and a 26-week treatment period. Participants who are taking less than 1500 mg/day metformin at screening will be titrated to a stable dose of at least 1500 mg metformin once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with metformin will be up to 42 weeks.
Study NCT00885352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glipizide
Description: Participants not meeting specific glycemic controls during the 26-week treatment period will use glipizide oral tablets as rescue therapy. In countries where glipizide is not available, participants will receive a sulfonylurea marketed in that country.
Study NCT00885352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glipizide
Description: Participants not meeting specific glycemic controls during the 26-week treatment period will use glipizide oral tablets as rescue therapy. In countries where glipizide is not available, participants will receive a sulfonylurea marketed in that country.
Study NCT03719365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVAPSV
Description: During the first trial, PSV will be set in order to obtain a Vt between 6 and 8 ml/kg; this support level will be defined as PSV100. Subsequently, the corresponding NAVA level (NAVA 100) will be determined using a dedicated ventilator function (NAVA Preview) which is able to estimate NAVA level in order to deliver an equivalent inspiratory peak pressure (Paw peak) compared to that obtained during PSV mode. Afterwards, PSV100 and NAVA100 will be first increased (PSV150 and NAVA150) during the second trial and then decreased during the third trial (PSV50 and NAVA150) by 50% from basal value. During the study period, PEEP and FiO2 will be kept equal to the values in use before patient enrollment.
Study NCT01502995 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser light (U-Step Walking Stabilizer with laser light)
Description: Use of a laser light on a rolling walker during episodes of freezing of gait.
Study NCT03290157 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ColoprAPP
Description: Additional downloaded SPA for reminding the crucial steps of colonoscopy preparation
Study NCT00852826 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard axillary lymphadenectomy
Description: Standard axillary lymphadenectomy
Study NCT00852826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen sponge coated with human coagulation factors
Description: Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
Study NCT04586777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transvertebral direct current stimulation (tvDCS)
Description: tvDCS is a painless, non-invasive form of spinal stimulation which delivers safe, low levels of electrical current to the spinal cord through the back. It is believed to be able to influence the excitability of the brain and spinal cord.
Study NCT04586777 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transvertebral direct current stimulation (tvDCS)
Description: tvDCS is a painless, non-invasive form of spinal stimulation which delivers safe, low levels of electrical current to the spinal cord through the back. It is believed to be able to influence the excitability of the brain and spinal cord.
Study NCT03142542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYDENA TAB.75mg(Udenafil 75mg)
Description: ZYDENA TAB.75mg(Udenafil 75mg): by mouth, Once daily, for 32 weeks
Study NCT03142542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet: by mouth, Once daily, for 32 weeks
Study NCT04410016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Staff Wellbeing Centres
Description: 2 Centres (rooms) accessible to staff for rest and relaxation, work breaks, supports advice and signposting. They are manned by support workers called Wellbeing Buddies.
Study NCT02413385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealtheSteps Program
Description: 6-month evidence-based lifestyle Rx program: At set time points over the 6-month period, participants have in-person visits with a HeS coach at the clinic setting. At each in-person session, the participant receives an individualized Rx for exercise, physical activity (step count) and healthy eating. The HeS Coach and participant then engage in a coaching/goal setting conversation to set detailed plans and goals to achieve their prescriptions. Participants independently choose which activities they will take part in to achieve their lifestyle Rx's and goals. In between in-person sessions, the participants have access to a suite of free-of-charge health technology support tools to: a) track their exercise, physical activity, and healthy eating; and b) receive virtual coaching and support.
Study NCT03145961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg intravenous infusion
Study NCT03075891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 1% cream
Description: Topical to the face, approximately one small pea size amount per facial region (right and left cheeks, forehead, chin, and nose) once a day for 12 weeks
Study NCT03075891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivermectin 1% cream
Description: Topical to the face, approximately one small pea size amount per facial region (right and left cheeks, forehead, chin, and nose) once a day for 12 weeks
Study NCT03075891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules
Description: 1 Capsule once-daily for 12 weeks
Study NCT03075891 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo capsules
Description: 1 Capsule once-daily for 12 weeks
Study NCT04264390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement-to-music
Description: Movement-to-music is a physical activity program that was developed onsite at a state-of-the-art adapted fitness facility. The program includes movements that are coupled with music to enhance muscular strength, cardiorespiratory capacity, flexibility, and balance. For this study, the program will be packaged into playlists of exercise videos that will be given to participants. Participants will be instructed to complete the prescribed videos 3 times per week. Participants will also be asked to attend 4 behavioral coaching calls with a telecoach. The goals of the behavioral coaching calls will be to address issues with the technology components of the program and promote physical activity participation within the community and adherence to the movement-to-music videos.
Study NCT02686866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bioelectrical impedance analysis (Bodystat, Quadscan 4000)
Study NCT02686866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dual-energy X-ray absorptiometry (Hologic, Delphi QDR)
Study NCT02686866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hand grip strength
Study NCT01388244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening
Description: Screening by risk factor assessment (FRAX) followed by DXA
Study NCT01388244 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Observation by use of register data
Study NCT03108586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental treatment
Description: Dental treatment of all dental needs present in adults related or not to the dental caries
Study NCT03108586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental treatment
Description: Dental treatment of all dental needs present in adults related or not to the dental caries
Study NCT02819180 — intervention group
Intervention type: BIOLOGICAL
Intervention: Butantan Influenza Trivalent, Fragmented and Inactivated vaccine
Study NCT00954512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT00954512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study NCT00954512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT00954512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT00954512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT00954512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Robatumumab
Description: In Part 1, robatumumab was to be administered at 10 mg/kg, 15 mg/kg (for Regimens B and C), or 20 mg/kg together with the assigned standard treatment. For Part 2, robatumumab was to be administered at the dose selected during Part 1, based upon the maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK) and pharmacodynamic (PD) data.
Study NCT00954512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT00954512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT04097405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-0120
Description: Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
Study NCT04097405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120
Description: Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
Study NCT04097405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
Study NCT00954512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT01346514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Addiction/Housing Case Management
Description: AHCM provided: 1) support in obtaining/maintaining housing through education about resources, coordination with VA and community housing program providers, assistance in establishing housing program eligibility, and problem-solving around threats to housing stability; 2) support for SUD and related issues that affect housing status through treatment engagement/re-engagement, referrals for needed services (e.g. psychiatric, medical, vocational), and addressing substance use issues proactively; 3) promotion of residential stability through Life Skills Training, which was designed to improve key skills (room and self-care, money management, and community participation).
Study NCT01346514 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Housing Support Group
Description: The HSG focused on gaining support from fellow study participants and learning from those who successfully obtained housing. Group facilitators provided education about housing resources and assistance with housing-related issues.
Study NCT02168790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amniotic membrane ring
Description: The amniotic membrane ring system (AmnioClip) is device for sutureless application of amniotic membrane to oculare surfaces. Amniotic membrane is mounted between the two rings with a specially designed, accessory mounting device.
Study NCT01097486 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoFuse
Description: Single Dose NeoFuse Surgical Implantation
Study NCT01097486 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allograft
Description: Single Dose Allograft Surgical Implantation
Study NCT01492491 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SUPRA-HFR
Description: usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen.
Study NCT04180241 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: POEM
Description: Peroral endoscopic myotomy
Study NCT00954512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Study NCT01754883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: Oral Lithium carbonate to target serum levle of 0.6-0.8.
Study NCT01959191 — intervention group
Intervention type: DRUG
Intervention: Dual antiplatelet therapy including aspirin and clopidogrel after off-pump coronary bypass surgery
Description: aspirin 100mg/day and clopidogrel 75mg/day, PO, from the day of surgery for 1 year
Study NCT04775121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterium Glucose
Description: Oral administration of 20 g Deuterium Glucose on a 3-hour
Study NCT04813601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATLAS 2030
Description: The participant will attend the laboratory every week, two days a week. The therapy will consist of the use of the exoskeleton for rehabilitative purposes. At the end of each three-month period, each patient's data will be monitored.
Study NCT00258180 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Administered IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover
Study NCT00258180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Administered IV over 1 hour on days 1-4
Study NCT02826590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck passive mobilizations
Description: Passive mobilizations performed to the neck of the participant by a Physiotherapist
Study NCT02826590 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Manual contact
Description: Manual contact applied to the neck of the participant by a Physiotherapist
Study NCT01516411 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Intervention for Lifestyle Eating/Exercise @ Stanford
Description: Participants are randomized to one of 4 groups, each of which uses a different Smartphone app to promote health behavior change
Study NCT02238717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865 (65mg)
Description: single oral dose (65 mg)
Study NCT02238717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865 (15mg)
Description: single oral dose (15mg)
Study NCT02238717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: single oral dose (300mg)
Study NCT02238717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching oral placebo
Study NCT01878123 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMP-110
Description: Dose levels 1 through 7: Single intravenous infusion on Day 0
Study NCT01878123 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose levels 4 through 7: Single intravenous infusion on Day 0
Study NCT01141270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFOLIA
Description: single sc injection, 225 IU
Study NCT01141270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-f
Description: single sc injection, 225IU
Study NCT03517618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1+leucovorin
Description: Eligible patients will receive TS-1 orally 40-60 mg (depending on patient's body surface area (BSA)) in combination with calcium folinate 30 mg twice a day for 7 days in a 2-week cycle.~The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study.
Study NCT00710372 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT006-AngQb
Description: s.c. injection
Study NCT00710372 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CYT006-AngQb
Description: s.c. injection
Study NCT02218840 — intervention group
Intervention type: OTHER
Intervention: Smoking topography
Description: Evaluation of cigar smoking topography
Study NCT01566929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie diet treatment
Description: Reduction of calorie intake to only 800 kcal/day by using LCD during 12 weeks
Study NCT01583023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: 150mg daily for first week, 300mg daily thereafter for a total of 8 weeks
Study NCT01583023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Repetitive Transcranial Magnetic Stimulation
Description: Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 5-second trains with a 10-second inter-train interval, for 30 trains per session. This treatment will be provided for the first 4 weeks of the study.
Study NCT01583023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 150mg daily first week, 300mg daily thereafter for a total of 8 weeks.
Study NCT01583023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham repetitive transcranial magnetic stimulation
Description: Sham rTMS will also begin their treatment 5 times a week for 4 weeks in junction with pharmacotherapy (Wellbutrin). Sham rTMS will be delivered at a frequency of 10 Hz and stimulation will be applied in 5-second trains with a 20-second inter-train interval, for 30 trains per session.
Study NCT03614338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small changes weight loss program
Description: This intervention uses a small-changes approach to calorie reduction (operationalized as 6 100-calories changes per day) along with increasing leisure-time physical activity and self-regulation strategies to produce weight loss. The intervention will be delivered via 12 face-to-face group sessions.